Insmed Inc Phase 3 ARISE Topline Results Transcript
Good morning. My name is Rob and I will be your conference operator today. At this time, I would like to welcome everyone to the Insmed Phase III ARISE Top Line Results Conference Call. (Operator Instructions). Bryan Dunn, Executive Director, Investor Relations, you may begin your conference.
Thank you, Rob. Good day, everyone and welcome to today's conference call to discuss the top line results of the Phase III ARISE study of ARIKAYCE in patients with newly diagnosed or recurrent MAC lung disease who have not started antibiotics.
I am joined today by Will Lewis, Chair and Chief Executive Officer; Martina Flammer, Chief Medical Officer; and Dr. Charles Daley, who is Chief of the Division of Mycobacterial and Respiratory Infections at National Jewish Health, a key opinion leader in the treatment of patients with NTM MAC lung infection and the primary investigator in the ARISE study.
The call will begin with opening remarks from Will before turning it over to Martina to walk us through the results. Following Martina, we will ask Dr. Daley
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
